ANALYSIS: Hanmi Deal Strengthens BI’s Hand But Competitors Ahead
This article was originally published in PharmAsia News
Executive Summary
Hanmi’s third-generation EGFR inhibitor HM61713, acquired for $50 million up front, strongly complements Boehringer Ingelheim’s existing oncology drug Gilotrif/Giotrif, but the new asset is facing competitors from AstraZeneca and Clovis that are more advanced in development.
You may also be interested in...
Boehringer Ingelheim Bullish In Oncology Despite Olmutinib U-Turn
Boehringer Ingelheim culled its late-stage lung cancer partnership with Hanmi after spending $65m in the first year because of the rapidly changing environment in the EGFR-positive lung cancer space. The German company doesn't intend to sit around licking its olmutinib-induced wounds, though, and is still committed to the lung cancer space.
Surprise Boehringer Decision Turns Hanmi Investors’ Hopes To Despair
Hanmi shares have gone on a wild roller coaster ride as bad news came after good. A day after it announced a huge licensing agreement with Genentech, the South Korean firm unveiled that Boehringer Ingelheim had decided to return rights to olmutinib, the EGFR inhibitor it licensed from Hanmi last July.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.